Company Profile

LumiraDx Limited is a point of care diagnostic company. The Company is focused on transforming community-based healthcare by providing critical diagnostic information to healthcare providers at the point of need. Its diagnostic testing solutions are being deployed globally by governments and healthcare institutions across laboratories, urgent care centers, physician offices, pharmacies, schools and others.

Employees

1,210

Sector

Advanced Medical Equipment & Technology

More about the company

22/07/24	BioPharma Credit PLC Notes the Update on the UK CMA (Competition and Markets Authority) Regarding the CMA's Clearance of the Proposed Acquisition of LumiraDx by Roche	CI
24/05/24	Roche, LumiraDx Deal Probed by U.K. Competition Watchdog	DJ
20/05/24	U.K. Competition Watchdog Weighs Potential Impact of Roche-LumiraDx	DJ
08/01/24	Top Midday Decliners	MT
08/01/24	LumiraDx Limited(OTCPK:LMDX.F) dropped from NASDAQ Composite Index	CI
02/01/24	Wall Street Set to Open 2024 Lower Amid Rise in Oil Prices, Ahead of Manufacturing, Construction Data	MT
02/01/24	Top Premarket Decliners	MT
30/12/23	Roche to buy part of LumiraDx diagnostics platform for $295 million	RE
30/12/23	LumiraDx Agrees to Sell Point-of-Care Tech Platform to Roche	DJ
01/12/23	Wall Street Set to Open Lower Friday as Investors Await Economic Data, Powell Speech	MT
01/12/23	Investors Look Ahead to Powell Speech as US Futures Trend Lower Friday	MT
01/12/23	Top Premarket Decliners	MT
07/11/23	LumiraDx Limited Announces Resignation of Lu Huang from the Board of Directors	CI

28/08/23	Raymond James Adjusts LumiraDx Price Target to $0.80 From $1, Maintains Outperform Rating	MT
17/05/23	Ladenburg Thalmann Adjusts Price Target on LumiraDx to $2.70 From $3.80, Maintains Buy Rating	MT
17/05/23	Goldman Sachs Adjusts Price Target on LumiraDx to $0.75 From $0.85, Maintains Neutral Rating	MT
17/05/23	Raymond James Adjusts Price Target on LumiraDx to $1 From $1.50, Maintains Outperform Rating	MT
22/03/23	Goldman Sachs Adjusts Price Target on LumiraDx to $0.85 From $1.20, Maintains Neutral Rating	MT

05/10/24	LumiraDx : NOTICE OF DISSOLUTION Form 6 K	PU
08/01/24	Stocks Commence 2024 Bullish Rally: LMDX, HNRC, BULT, HALB, SPZI	AQ
06/01/24	LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th	GL
02/01/24	Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform	AQ
30/12/23	LumiraDx : EXPLANATORY NOTE - Form 6-K	PU

24/05/24	Britische Wettbewerbsaufsicht CMA prüft Roche-LumiraDx-Deal
20/05/24	CMA wägt mögliche Auswirkungen von Roche-LumiraDx-Deal ab
14/11/22	Mit HbA1c-Test erweitert LumiraDx erneut sein Mikrofluidik-Point-of-Care-Diagnostik-Portfolio
14/11/22	Mit HbA1c-Test erweitert LumiraDx erneut sein Mikrofluidik-Point-of-Care-Diagnostik-Portfolio

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LUMIRADX	+900.00%	-.--%	-	-	3.59M
THERMO FISHER SCIENTIFIC, INC.	+1.00%	+0.56%	+21.18%	+55.21%	249B
DANAHER CORPORATION	+1.00%	+4.09%	+5.71%	+20.62%	162B
INTUITIVE SURGICAL, INC.	+0.39%	+4.86%	-17.60%	+75.03%	157B
BOSTON SCIENTIFIC CORPORATION	-0.27%	+0.90%	-55.62%	-8.69%	66.22B
VEEVA SYSTEMS INC.	-0.71%	+1.39%	+8.62%	+68.92%	52.3B
SIEMENS HEALTHINEERS AG	+0.84%	+3.05%	-14.55%	-8.31%	52.18B
EDWARDS LIFESCIENCES CORPORATION	+1.02%	+3.00%	+11.16%	+43.10%	51.34B
AGILENT TECHNOLOGIES, INC.	+1.71%	+3.83%	+20.34%	+69.11%	48.79B
WATERS CORPORATION	+1.26%	+5.90%	+30.74%	+88.13%	44.57B
Average	+90.56%	+2.12%	+1.11%	+44.79%	98.17B
Weighted average by Cap.	+0.68%	+1.40%	+2.70%	+46.38%

LUMIRADX Stock

Stocks

LMDX

KYG5709L1095

Advanced Medical Equipment & Technology

Latest news: LUMIRADX

Analysts' recommendations: LUMIRADX

Press Releases: LUMIRADX

News in other languages: LUMIRADX

Quotes and Performance

Other Advanced Medical Equipment & Technology

Company Profile